Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue: −33.6%
EPS: +21.2%
Free cash flow: −30.0%

Quarter to June 2026, against a year earlier

38.93 2.31 +6.31%

Follow ROIV

Alert me

Market cap: $26.5B
P/E: 0.0×
Fwd P/E: −27.7×
Dividend yield: —
F-score: 2/9
Altman Z: 28.31
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Roivant Sciences Ltd. 10-Q filed Aug 6, 2026

Fiscal Q1 2026 · Period ended Jun 30, 2026 · Filed Aug 6, 2026 · accepted 7:28 AM ET · Document on sec.gov · Filing index

Red flags

Share dilution Aug 6, 2026
Shares outstanding rose 5.8% in a year, to 722.3 million

10-Q filed Aug 6, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 11, 2025: 16 added · 21 removed · 32 modified; 4 with only figures updated

Roivant Sciences Ltd. 10-Q filed Aug 6, 2026

Red flags

What changed

Stockrow Weekly